UNSPSC 51333000: Antipsychotic indoles

Antipsychotic drugs made from benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.

UNSPSC 51333000 Antipsychotic indoles is a Class code that in recent state and local solicitations actually encompasses acquisition of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products rather than antipsychotic medications specifically. State and local purchasing under this code reflects community health emergency response, pharmaceutical distribution programs serving multiple jurisdictions through cooperative purchasing vehicles, and pharmacy benefit program modernization. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering procurement on behalf of member state and local facilities across Oregon and other participating jurisdictions). The code sees activity from specialized pharmaceutical procurement programs including direct-to-manufacturer prescription initiatives and competitive bidding for pharmaceutical product supply through authorized wholesale channels.

Recent opportunities reflect geographic spread across Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries required to the Seminole County Community Health Building; the procurement included FEMA funding and required E-Verify compliance, drug-free workplace certification, and specific insurance coverage. Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program enabling state agencies and self-insured health plans to bypass traditional pharmacy benefit managers and wholesalers. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP on January 20, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products with an March 26, 2026 response deadline, requiring vendors to partner with designated wholesalers (Cencora, Cardinal Health, Morris & Dickson), comply with cGMP and Drug Supply Chain Security Act standards, and accept a 3 percent administrative fee on all contract purchases.